These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23392639)

  • 1. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Christadoss P
    Curr Protoc Immunol; 2001 May; Chapter 15():Unit 15.8. PubMed ID: 18432738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
    Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
    J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
    Fuchs S; Aricha R; Reuveni D; Souroujon MC
    J Autoimmun; 2014 Nov; 54():51-9. PubMed ID: 24970384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.
    Luo J; Lindstrom J
    Autoimmunity; 2012 May; 45(3):245-52. PubMed ID: 21950318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Luo J; Lindstrom J
    Ann N Y Acad Sci; 2018 Feb; 1413(1):76-81. PubMed ID: 29377167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
    Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
    Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
    Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
    J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
    Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
    Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats.
    Baggi F; Annoni A; Ubiali F; Milani M; Longhi R; Scaioli W; Cornelio F; Mantegazza R; Antozzi C
    J Immunol; 2004 Feb; 172(4):2697-703. PubMed ID: 14764745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
    Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
    J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.